SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top e ...

Healthcare perhaps represents one of the most exciting applications of AI technologies. The next generation of medical breakthroughs and advancements are likely to be powered by AI. Tempus AI, Inc. (NASDAQ: TEM ) is aPlease consider following my new X/Twitter account for reaction to market developments and news.I'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma ...

Core Insights - Tempus AI and Guardant Health are leading companies in AI-powered precision oncology, with Tempus reporting a 75% year-over-year revenue growth in Q1 2025, driven by genomics testing demand and a $200 million data licensing deal with AstraZeneca and Pathos [1][6] - Guardant Health is enhancing its position in liquid biopsy and early cancer detection, achieving positive gross margins for the first time in Q1 2025 [1][10] Company Performance - Tempus AI's revenue growth is attributed to a 89% increase in genomics revenues, with gross profit nearly doubling (up 99.8% year-over-year) and adjusted EBITDA improving by $27.8 million [6][9] - Guardant Health raised its 2025 revenue guidance to $880-$890 million, driven by increased test volume and average selling prices, with oncology revenues projected to grow 18% [10][12] Strategic Developments - Tempus AI is transitioning from a clinical testing provider to a data-driven platform, with a total remaining contract value exceeding $1 billion due to its strategic partnerships [7] - Guardant Health's Reveal product has turned gross margin positive, benefiting from reduced costs and improved reimbursement, positioning it for high growth in minimal residual disease detection [11][12] Financial Outlook - Tempus AI has raised its full-year guidance to $1.25 billion, indicating around 80% annual growth, despite posting a Q1 adjusted EBITDA loss of $16.2 million [8][9] - Guardant Health expects to reach breakeven for non-screening operations by Q4 2025, with projected cash burn significantly reduced to $25-$35 million for the year [12][13] Valuation Comparison - Tempus AI is trading at a forward price-to-sales ratio of 8.48, while Guardant Health's ratio is 6.22, indicating that Tempus AI is relatively more expensive compared to Guardant Health [14] - Analysts suggest a potential decline of 5.2% for Tempus AI's stock price, while Guardant Health's average price target indicates a 16.1% upside [15][17] Investment Considerations - Both companies are seen as strong long-term plays in AI-powered precision oncology, but Guardant Health is currently better positioned due to its improving gross margins and disciplined cash management [20]

LOS ANGELES, June 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Tempus is the subject of a report published by Spruce Point Capital Management on Ma ...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Tempus AI, Inc. (NASDAQ: TEM)?Did you purchase your shares between August 6, 2024 and May 27, 2025, inclusive?Did you lose money in your ...

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Class Action Lawsuit Details - The lawsuit is titled Shouse v. Tempus AI, Inc., and it allows purchasers of Tempus AI common stock between August 6, 2024, and May 27, 2025, to seek appointment as lead plaintiff by August 12, 2025 [1]. - The lawsuit claims that Tempus AI inflated the value of contract agreements, had questionable joint ventures, and engaged in potentially unethical billing practices [3]. - On May 28, 2025, a research report from Spruce Point Capital Management raised concerns about Tempus AI's management and operations, resulting in a stock price drop of over 19% [4]. Group 2: Allegations Against Tempus AI - Allegations include that Tempus AI's joint venture with SoftBank appeared to involve "round-tripping" capital, and that AstraZeneca reduced its financial commitments through a questionable payment structure [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is under scrutiny for aggressive billing practices that could threaten its sustainability [3]. - The issues raised in the lawsuit indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Insights - Tempus AI reported $193.8 million in Genomics revenues for Q1 2025, marking an increase of nearly 89% year over year, driven by a 20% growth in oncology test volumes and higher average revenue per test due to increased Medicare reimbursement rates [1][8] - The company is set to launch a new liquid biopsy assay, xM for treatment response monitoring, which will track changes in tumor fraction during immune-checkpoint inhibitor therapies, potentially influencing treatment decisions [2] - Tempus is also preparing to launch its first whole-genome sequencing test, Xh, aimed at detecting clinically relevant variants in hematological oncology by next year [3] - A companion diagnostic test is being developed in collaboration with Verastem Oncology, leveraging Tempus' FDA-approved xT CDx assay in clinical trials for ovarian cancer treatment [4] Industry Updates - Guardant Health reported a 20% year-over-year growth in oncology revenues, with a 25% increase in test volumes, and launched a hereditary cancer test [5] - Exact Sciences is experiencing strong international adoption of its Oncotype DX genomic test and has launched Cologuard Plus, which is expected to reduce false positives significantly [6] Financial Performance - Tempus AI shares have increased by 105.3% year to date, outperforming the industry average growth of 28% [7] - The company is trading at a forward Price-to-Sales ratio of 8.60X, compared to the industry average of 6.02X [9] - The Zacks Consensus Estimate for Tempus AI's 2025 earnings has been trending upward over the past 90 days, indicating positive market sentiment [11]

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Eastern District of Illinois on behalf of investors (the “Class”) who purchased or acquired the common stock of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) between August 6, 2024 and May 27, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and cert ...

Core Viewpoint - Tempus AI, Inc. is facing a securities class action lawsuit for failing to disclose material information during the class period, which has led to a significant drop in its stock price [3][5]. Group 1: Lawsuit Details - Investors have until August 12, 2025, to file lead plaintiff applications if they purchased shares between August 6, 2024, and May 27, 2025 [1]. - The lawsuit is pending in the United States District Court for the Northern District of Illinois [1]. - The case is identified as Shouse v. Tempus AI, Inc., et al., No. 25-cv-06534 [5]. Group 2: Allegations Against Tempus - Tempus and its executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. - Spruce Point Capital Management reported several issues, including overstated AI capabilities, a history of executives cashing out before losses, and aggressive accounting practices [4]. - Concerns were raised regarding the AstraZeneca and Pathos AI deal, as well as a recent revision in financial guidance indicating weaknesses in core operations [4]. Group 3: Market Reaction - Following the news of the lawsuit and allegations, Tempus' share price fell by $12.67, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [5].